Pharmaceutical

MesoCancerVac by Amphera for Metastatic Pancreatic Cancer: Likelihood of Approval

MesoCancerVac is under clinical development by Amphera and currently in Phase I for Metastatic Pancreatic Cancer.

Jul 7, 2023 - 20:00
MesoCancerVac is under clinical development by Amphera and currently in Phase I for Metastatic Pancreatic Cancer.
Read the original article

Tags:

Previous Article

Selinexor by Karyopharm Therapeutics for Osteosarcoma: Likelihood of Approval

Next Article

ABBV-101 by AbbVie for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood o...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pulse oximeters’ inaccuracies in darker-skinned people require urgent action, AGs tell FDA

Pulse oximeters’ inaccuracies in darker-skinned people ...

Nov 7, 2023

Oscotec sees highest patent filings and grants during June in Q2 2024

Oscotec sees highest patent filings and grants during J...

Jul 22, 2024

Did you have Obamacare on your GOP debate bingo card?

Did you have Obamacare on your GOP debate bingo card?

Sep 28, 2023